Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257359 | 0.92 | MAPT (0.43) | PTGER1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7456019 | 0.86 | PTGER1 (0.41) | PTGER1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2581362 | 0.78 | KEAP1 (0.47) | KEAP1NFE2L2GAA | |
| SCHEMBL5026438 | 0.77 | PTGER1 (0.38) | POLBPTGER1MAPTMEN1KMT2A | |
| SCHEMBL8370091 | 0.76 | KEAP1 (0.45) | MEN1KMT2AKEAP1NFE2L2GAA | |
| SCHEMBL7257038 | 0.76 | KEAP1 (0.48) | MAPTMEN1KMT2AMMP1MMP9 | |
| SCHEMBL7447488 | 0.73 | CYP2C9 (0.43) | POLBMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5981554 | 0.72 | MCL1 (0.39) | MAPTMEN1KMT2AHPGDGAA | |
| SCHEMBL7452491 | 0.72 | KEAP1 (0.50) | MMP1MMP9MMP13KEAP1NFE2L2 | |
| SCHEMBL6395395 | 0.71 | KEAP1 (0.36) | PTGER1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141609-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | POLB 898/4885PTGER1 3303/4885MAPT 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.